Table 1.
Groups of mice with different treatments in vivo experiments.
Groups | NSS (mLkg−1d−1) | Cy (mgkg−1d−1) | NSS (mLkg−1d−1) | LP3 (mgkg−1d−1) | Ganoderan (mgkg−1d−1) |
Intraperitoneal injection (days 1–3) | Peroral administration (days 4–18) | ||||
Normal control | 5 | – | 5 | – | – |
Model control | – | 80 | 5 | – | – |
LP(I) | – | 80 | – | 50 | – |
LP(II) | – | 80 | – | 100 | – |
LP(III) | – | 80 | – | 200 | – |
Ganoderan | – | 80 | – | – | 50 |
NSS: normal sodium solution; Cy: cyclophosphamide; LP3: longan pulp polysaccharide-protein complex 3.